Cybin (HELP) Liabilities and Shareholders Equity (2021 - 2026)

Cybin (HELP) posted quarterly Liabilities and Shareholders Equity of $251.2 million for Q1 2026, up 39.35% year-on-year from $180.2 million in Q1 2025, and down 13.42% on a QoQ basis from $290.1 million in Q4 2025.

Cybin (HELP) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends

Cybin (HELP) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $251.2 million the latest figure, recorded in Q1 2026.

  • Quarterly Liabilities and Shareholders Equity rose 39.35% year-over-year to $251.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $933.3 million (up 22.45% YoY) and the FY2026 annual result came in at $251.2 million, up 35.01% from the prior year.
  • Liabilities and Shareholders Equity eased to $251.2 million in Q1 2026 per HELP's latest filing, from $290.1 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for HELP reached as high as $290.1 million in Q4 2025 and fell as low as $33.8 million in Q1 2023.
  • A 5-year average of $149.8 million and a median of $181.2 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity tumbled 40.77% — and 2024, when it jumped 347.47%.
  • Year by year, Liabilities and Shareholders Equity stood at $44.7 million in 2022, then surged by 113.11% to $95.3 million in 2023, then soared by 90.48% to $181.5 million in 2024, then soared by 59.84% to $290.1 million in 2025, then declined by 13.42% to $251.2 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $251.2 million, $290.1 million, and $181.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 Cybin 28.04 Mn 28.04 Mn - 251.17 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 251.17 Mn
Dec 31, 2025 290.11 Mn
Sep 30, 2025 181.25 Mn
Jun 30, 2025 210.81 Mn
Mar 31, 2025 180.24 Mn
Dec 31, 2024 181.50 Mn
Sep 30, 2024 192.35 Mn
Jun 30, 2024 208.12 Mn
Mar 31, 2024 224.14 Mn
Dec 31, 2023 95.29 Mn
Sep 30, 2023 42.99 Mn
Jun 30, 2023 57.54 Mn
Feb 28, 2023 33.80 Mn
Dec 31, 2022 44.71 Mn
Sep 30, 2022 52.99 Mn
Dec 31, 2021 75.49 Mn
Sep 30, 2021 83.78 Mn
Jun 30, 2021 67.39 Mn
Mar 31, 2021 72.78 Mn